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Introduction
Mevalonate kinase deficiency (MKD) is a rare autoin-
flammatory, autosomal-recessive defect on MVK gene.
Clinical spectrum ranges from recurring febrile attacks
to malformations and neurologic disorders. Gastrointest-
inal symptoms are cardinal. Severe gastrointestinal
involvement has been described at the onset.
Objective
To analyse severe gastrointestinal events (SGE) compli-
cating MKD.
Patients and methods
Retrospective observational French cohort of MKD
patients. SGE were defined as complicated inflammatory
involvement, requiring an abdominal surgery and/or
enteral/parenteral nutrition. Data were collected from
clinical charts provided by the members of the Franco-
phone Society for Paediatric Rheumatism and Inflamma-
tory Diseases (SOFREMIP).
Results
From a 53-patient cohort, nine presented a SGE (17%).
From these, disease onset median age was 1.0 months
(0-12); one patient deceased (22 months) from a non-
gastrointestinal event. Compound heterozygote mutations
were found in 7/8, being Val377Ile the commonest (6/8).
The main symptoms during febrile attacks were: diarrhoea
(100%, 7/7), lymphadenopathy (89.9%, 8/9), skin lesions,
joint pain (85.7%, 6/7 each), aphtous ulcers, abdominal
pain (83.3%, 5/6 each), splenomegaly (66.7%, 6/9), hepato-
megaly (62.5%, 5/8) and vomiting (57.1%, 4/7). Median
mevalonic aciduria: 23.05 mmol/mol of creatinine
(P25=13.7; P75=55.5); median MK activity: 2.2% (P25=1.0;
P75=24.0). The significant co-morbidities found in SGE
patients in comparison with the global cohort were: fail-
ure-to-thrive in 85.7% (6/7), pulmonary diseases in 37.5%
(3/8) and feeding disorders in 28.6% (2/7) (p<0.05).
Severe gastrointestinal involvement was the first event in
6% (3/50), representing 43% (3/7) of patients with severe
gastrointestinal disease: abdominal adhesions (66.6%, 6/9)
and colitis/enterocolitis (4/9, 44.4%) were mainly found.
87.5% (7/8) needed surgery and 44.4% (4/9) required
enteral/parenteral nutrition. Despite digestive resection,
disease progression remained; two patients needed re-
intervention due to surgical complications. Aphtous/
ulcerative damage was the main endoscopic feature (4/9,
44.4%). The most consistent microscopic finding was
lymphocytic infiltrates. IL-1 antagonists were the most
used/effective treatment (4/9), resulting in with complete
remission in all three patients with data available.
Conclusion
MKD severe gastrointestinal involvement presentation
has a non-negligible frequency. It usually appears as an
aphtous/ulcerative disease involving any part of the
digestive tract or as abdominal adhesions, frequently
requiring surgery. The treatment with IL-1 antagonists
resulted in complete remission in a majority of treated
patients. Thus, MKD should be added to the list of
monogenic early-onset inflammatory bowel disease.
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